BioCentury | Sep 4, 2020
Tools & Techniques

Human germline editing report takes first steps toward concrete scientific guidelines

A report released Wednesday by an expert panel on human germline editing is the first to go beyond calls for caution and consensus and start to spell out technical definitions of safety.  Like every other...
BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

...diversity of different types of data and things they cover because you put together that mosaic...
BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

...B cells that correlated with protection against SIV infection in non-human primates that received a mosaic...
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...Prevention B.V. unit of Johnson & Johnson (NYSE:JNJ) and partners said they will test a mosaic-based...
...for which initial results are expected in 2021 (see "J&J begins Phase IIb Trial of Mosaic...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

We’ve moved on from sound and fury. We’re now just signifying nothing. The latest public proclamation on germline gene editing, couched in a call for a moratorium, is as much preaching to the choir as...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Oct 31, 2018
Translation in Brief

Programming cell circuits

...regulated by TEV protease, TVMV protease, turnip mosaic virus protease (TuMV protease) and sunflower mild mosaic...
...protease (TEV protease) Tobacco vein mottling virus protease (TVMV protease) Cancer (unspecified) sunflower mild mosaic virus protease TuMV protease turnip mosaic...
BioCentury | Apr 13, 2018
Company News

Israeli government launches digital health plan

...digital health research and development by Israeli companies. The digital health plan will establish the "Mosaic"...
BioCentury | Jan 5, 2018
Financial News

Bioinformatics company DNAnexus raises $58M in financing

...the company's total raised capital to about $110 million. Earlier this year, DNAnexus launched the Mosaic...
Items per page:
1 - 10 of 87
BioCentury | Sep 4, 2020
Tools & Techniques

Human germline editing report takes first steps toward concrete scientific guidelines

A report released Wednesday by an expert panel on human germline editing is the first to go beyond calls for caution and consensus and start to spell out technical definitions of safety.  Like every other...
BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

...diversity of different types of data and things they cover because you put together that mosaic...
BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

...B cells that correlated with protection against SIV infection in non-human primates that received a mosaic...
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...Prevention B.V. unit of Johnson & Johnson (NYSE:JNJ) and partners said they will test a mosaic-based...
...for which initial results are expected in 2021 (see "J&J begins Phase IIb Trial of Mosaic...
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

We’ve moved on from sound and fury. We’re now just signifying nothing. The latest public proclamation on germline gene editing, couched in a call for a moratorium, is as much preaching to the choir as...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Oct 31, 2018
Translation in Brief

Programming cell circuits

...regulated by TEV protease, TVMV protease, turnip mosaic virus protease (TuMV protease) and sunflower mild mosaic...
...protease (TEV protease) Tobacco vein mottling virus protease (TVMV protease) Cancer (unspecified) sunflower mild mosaic virus protease TuMV protease turnip mosaic...
BioCentury | Apr 13, 2018
Company News

Israeli government launches digital health plan

...digital health research and development by Israeli companies. The digital health plan will establish the "Mosaic"...
BioCentury | Jan 5, 2018
Financial News

Bioinformatics company DNAnexus raises $58M in financing

...the company's total raised capital to about $110 million. Earlier this year, DNAnexus launched the Mosaic...
Items per page:
1 - 10 of 87